FIELD: medicine.
SUBSTANCE: inventions relate to a recombinant lactic acid bacterium (hereinafter – LAB) for polypeptide delivery and its use. The recombinant LAB for polypeptide delivery contains the first exogen nucleic acid encoding a hybrid protein containing (A) N-end mucin-binding polypeptide, while the specified mucin-binding polypeptide is a “trefoil” factor 3 (TFF3), and (B) C-end cell-adhesive polypeptide that contains a domain of anchoring in a cell wall, while the specified cell-adhesive polypeptide is CmbA. Nucleic acid encoding the mentioned hybrid protein is also proposed. A pharmaceutical composition for polypeptide delivery containing the specified LAB, the use of the specified LAB, and the use of the specified pharmaceutical composition, as well as a method for the treatment of a metabolic disease in a subject who needs it, in which the specified LAB or the specified pharmaceutical composition is used, are also proposed.
EFFECT: inventions allow for ensuring increased adhesion to the intestinal mucosa and increasing the time of transition of modified cells of the recombinant LAB through the gastrointestinal tract.
27 cl, 9 dwg, 4 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF LACTATE FROM C1-COMPOUNDS USING TRANSFORMANTS OF LACTATE DEHYDROGENASE | 2014 |
|
RU2710714C2 |
| POLYPEPTIDE CONSTRUCTIONS LYSINE-ANTIMICROBIAL PEPTIDE (AMP), LYSINES, ISOLATED ENCODING POLYNUCLEOTIDES AND VARIANTS OF THEIR APPLICATION | 2019 |
|
RU2803121C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| COMPOSITIONS AND METHODS FOR TREATING TYPE 1 DIABETES | 2017 |
|
RU2760997C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| ORAL CARE PRODUCTS AND METHODS CONTAINING HLP | 2016 |
|
RU2759134C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
